A method of treating and/or managing cystic fibrosis (CF) and/or other infectious or inflammatory lung disease or mucosal surface condition in a patient in need thereof, using a drug formulation with beneficial and/or synergistic effects among ingredients which comprise the formulation herein reported. Cystic fibrosis disease is characterized by loss of homeostatic balance at mucosal surfaces, resulting in persistent infection, excessive sticky mucus and tissue-destructive host inflammatory responses. When used to treat lung disease, this invention is delivered to airways as an inhaled dose by nebulizer. The formulation(s) arising from this invention are preferably composed of natural endogenous compounds already found within the body but possibly obtained from other sources, and/or of plant phytochemicals, which in combinations herein disclosed, have synergistic hydrating, anti-inflammatory and antimicrobial properties as well as direct corrector and/or potentiator effects and/or other modulating effects on CFTR function when administered to mucosal surface where CFTR with some residual function is achieved. Synthetic molecules can also be used.